Evidence map›Paper›PMID 21325671›Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2011

Molecular mechanisms affecting fibrin structure and stability.

Susan T Lord

Abstract readReview
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Red blood cell-derived transglutaminase 2 influences thrombus formation.Research and practice in thrombosis and haemostasis · 2026
    Article
  7. Review
  8. Article
  9. Influence of the Immune Checkpoint Inhibitors on the Hemostatic Potential of Blood Plasma.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Regulation of fibrinogen synthesis.Thrombosis research · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Susan T LordDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7525, USA. stl@med.unc.edu

Funding

MUTAGENIC STUDIES OF FIBRINOGEN ALPHA CHAIN FUNCTIONR01HL031048 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LORD, SUSAN T · 1987 to 2010
$3.5M
A GENETIC APPROACH TO THE FIBRINOGEN-FIBRIN CONVERSIONR23HL031048 · NHLBI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI LORD, SUSAN T · 1985 to 1986
–
NHLBI NIH HHS HL031048NHLBI NIH HHS R01 HL031048
6 · The paper itself

Abstract

Fibrin structure and stability have been linked to many thrombotic diseases, including venous thromboembolism. Analysis of the molecular mechanisms that affect fibrin structure and stability became possible when the crystal structure of fibrinogen was solved. Biochemical studies of natural and recombinant variant fibrinogens have examined the interactions that mediate the conversion of soluble fibrinogen to the insoluble fibrin network. These studies identified intermolecular interactions that control fibrin structure, although some critical events remain ambiguous. Studies show that fibrin structure modulates the enzymatic lysis of the fibrin network, so the molecular mechanisms that control structure also control stability. Studies show that the mechanical stability of the fibrin clot depends on the properties of the fibrin monomer, leading investigators to explore the molecular basis of the monomer's mechanical properties. The work summarized here provides insights that might allow the development of pharmaceuticals and treatments to modulate fibrin structure and stability in vivo and thereby prevent or limit thrombotic disease.

Indexed as

Blood CoagulationAnimalsFibrinFibrinogenFibrinolysisFibrinolytic AgentsHumansProtein ConformationStructure-Activity RelationshipVenous ThrombosisFibrinFibrinogenFibrinolytic Agents

Identifiers

PMID21325671
PMCPMC3070401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.